Literature DB >> 2743869

Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.

G Ravizzola1, G Pinsi, F Pirali, D Colombrita, I Foresti, L Peroni, A Turano.   

Abstract

Rufloxacin (MF-934) is a new quinolone which shows in vitro antibacterial activity against E. coli, Salmonella, Klebsiella, Proteus and Staphylococcus spp. Lower in vitro activity was observed with Pseudomonas, Serratia, Enterobacter and the streptococci group D. The antimicrobial activity of MF-934 in vitro is higher than that of nalidixic acid but lower than that of ciprofloxacin, ofloxacin, pefloxacin or norfloxacin. The protective effects of MF-934 in systemic infections in mice are lower than those of ciprofloxacin and ofloxacin. In respiratory infections in rats and in subcutaneous infections in guinea-pigs, the protective effects of MF-934 are of the same order as ciprofloxacin and ofloxacin. This is probably due to the pharmacokinetic properties of MF-934, i.e. the long half-life and tissue concentrations higher than plasma levels.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2743869

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN： 0378-6501


  8 in total

1.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

4.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

Authors:  J C Kisicki; R S Griess; C L Ott; G M Cohen; R J McCormack; W M Troetel; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

6.  High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.

Authors:  T B Vree; M van den Biggelaar-Martea; B P Imbimbo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

7.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

8.  Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.

Authors:  R Rimoldi; M Fioretti; A Albrici; B P Imbimbo
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.